Dulaglutide clinical trials
Also written LY2189265.
How each study uses dulaglutide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dulaglutide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Sept 2014 · TRULICITY · BLA 125469 (FDA, Drugs@FDA)
- European Union
- 21 Nov 2014 · Trulicity · EMEA/H/C/002825 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
78 studies that test it; most in 2010 (8)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 8 |
| 2011 | 8 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 47 · Other 31
Eli Lilly and Company (45) · University Hospital, Basel, Switzerland (4) · Zagazig University (2) · Ain Shams University (2) · Emory University (2) · Attikon Hospital (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Semaglutide (2) · Tirzepatide (2) · Empagliflozin (2) · Nisotirostide (2) · DPP-4 inhibitors (1) · Metformin (1) · Canagliflozin (1) · Dapagliflozin (1)
Related medicines
As reviewed, each with the page that says it.
- One of GLP-1 receptor agonists source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Dulaglutide is the comparator. A study of two new drugs counts under both.
- 1HS-20094 · Jiangsu Hansoh Pharmaceutical Co., Ltd. · next primary completion Mar 2027
- 1Orforglipron · Eli Lilly and Company · next primary completion Mar 2030
Reaching primary completion within a year · 3
Studies that test dulaglutide.
- Dec 2026Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusPhase 1/2 · Ain Shams University
- Apr 2027Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseasePhase 4 · First Affiliated Hospital of Wannan Medical College
- Jun 2027GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntolerancePhase 2 · University of Pennsylvania
Studies
Open first, then newest update. How each study uses dulaglutide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 78
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesRecruitingPhase 2AdventHealth Translational Research InstituteNCT05478707Written as Dulaglutide
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)RecruitingPhase 3Eli Lilly and CompanyNCT06739122Written as Dulaglutide
- Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusEnrolling by invitationPhase 1/2Ain Shams UniversityNCT07319286Written as Dulaglutide
- GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceRecruitingPhase 2University of PennsylvaniaNCT04731272Written as Dulaglutide 0.75Mg/0.5Ml Inj Pen
- GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryRecruitingPhase 4The University of Hong KongNCT06324461Written as Dulaglutide 0.75mg subcutaneous injection
- Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNot yet recruitingPhase 4First Affiliated Hospital of Wannan Medical CollegeNCT07537088Written as Dulaglutide
- Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisRecruitingPhase 2/3National University of SingaporeNCT07282041Written as Dulaglutide
- The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With ObesityRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT06331286Written as dulaglutide injection
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNot yet recruitingPhase 4Seoul National University Bundang HospitalNCT05140694Written as Dulaglutide
- Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesCompletedPhase 3Zagazig UniversityNCT07834398Written as Dulaglutide
- Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialCompletedPhase 3Zagazig UniversityNCT07820111Written as Dulaglutide 1.5 MG/ML
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedPhase 4Fundación para la Investigación del Hospital Clínico de ValenciaNCT06851962Written as Dulaglutide
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT07313813Written as Dulaglutide
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusCompletedPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06235086Written as Dulaglutide
- Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaCompletedPhase 2Ain Shams UniversityNCT07370922Written as Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseCompletedPhase 2Vanderbilt University Medical CenterNCT05254418Written as dulaglutide injection
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaCompletedPhase 4Eli Lilly and CompanyNCT05659537Written as Dulaglutide
- Perioperative Stress Hyperglycemia in General and Vascular Surgery PatientsTerminatedPhase 4Emory UniversityNCT04862234Written as Dulaglutide
- GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic ResponseCompletedPhase 4The University of Texas Health Science Center, HoustonNCT04387201Written as Dulaglutide
- Basal Plus GLP1-ra on Glycemic Variability in CKDCompletedPhase 4Elaine ChowNCT05218915Written as Dulaglutide
See all 78 studies that test dulaglutide →
Given beside what is tested · 2 — dulaglutide is usual care or a partner of the new treatment
- Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMCompletedPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT04466904Written as Dulaglutide
- A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01468181Written as LY2189265
As the comparator · 25 — what is tested is compared with dulaglutide
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07668336Written as Dulaglutide
- Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNot yet recruitingPhase 2ProGen. Co., Ltd.NCT07677891Written as Dulaglutide
- A Phase 3 Study of HS-20094 in Patients With T2DMNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07156539Written as Dulaglutide Injection
- A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminRecruitingPhase 2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07109700Written as Dulaglutide 1.5 MG
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT04255433Written as Dulaglutide
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminActive, not recruitingPhase 3Beijing Dongfang Biotech Co., Ltd.NCT06257966Written as Dulaglutide
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)CompletedPhase 4Eli Lilly and CompanyNCT05564039Written as Dulaglutide
- A Study of HS-20094 in Patients With T2DMCompletedPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06901648Written as Dulaglutide
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMCompletedPhase 3Hangzhou Sciwind Biosciences Co., Ltd.NCT05680129Written as Dulaglutide
- A Study of LY3493269 in Participants With Type 2 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT04515576Written as Dulaglutide
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusCompletedPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT05516966Written as Dulaglutide Injection
- A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)CompletedPhase 1Eli Lilly and CompanyNCT02759107Written as Dulaglutide
- A Study of LY3502970 in Participants With Type 2 Diabetes MellitusCompletedPhase 2Eli Lilly and CompanyNCT05048719Written as Dulaglutide
- A Study of LY3437943 in Participants With Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT04867785Written as Dulaglutide
- The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.Status unknownPhase 4Second Xiangya Hospital of Central South UniversityNCT05005741Written as Dulaglutide
- Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide scCompletedPhase 4Novo Nordisk A/SNCT04189848Written as Dulaglutide
- A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT05459285Written as dulaglutide injection
- A Study of TG103 Injection in Type 2 Diabetes SubjectsStatus unknownPhase 2CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT05348122Written as Dulaglutide,QW
- A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT03861052Written as Dulaglutide
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedPhase 3SanofiNCT02787551Written as dulaglutide
Showing 20 of 25.
Codes
What other systems call dulaglutide · ClinicalTrials.gg INT005774
- MeSH (NLM) C555680dulaglutideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WTT295HSY5DULAGLUTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1551291Confirmed FDA, Wikidata
- Wikidata Q21011228dulaglutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169923DulaglutideOne source FDA
- DrugBank DB09045One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C555680 | dulaglutide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WTT295HSY5 | DULAGLUTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1551291 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011228 | dulaglutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169923 | Dulaglutide | One source FDA |
| DrugBank | DB09045 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.